Silence Therapeutics plc (SLN) had recently reported positive results from its phase 2 ALPACAR-360 study using its drug zerlasiran [SLN360] for the treatment of patients who are at risk of ...

Researchers reviewed evolving ASCVD risk calculators and lipid management strategies for potential updates to international cholesterol guidelines.

A novel oral molecule significantly reduced inflammatory markers linked to development of arteriosclerotic cardiovascular ...

Verve Therapeutics, Inc. (VERV) has been making great progress in being able to advance its pipeline, that's because it has done well to advance its main clinical candidate in the pipeline known as ...

Taking into account estimated 30-year risk of atherosclerotic cardiovascular disease (ASCVD) enables clinicians to identify which patients may benefit from starting primary-prevention strategies ...

Tirzepatide (Mounjaro; Eli Lilly), a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide ...

Atherosclerotic cardiovascular disease (ASCVD) caused by atherosclerosis is one of the leading causes of death worldwide.

A risk calculator that incorporates established cardiovascular risk factors and additional cardiac biomarkers, such as high-sensitivity C-reactive protein (hs-CRP) and N-terminal pro-B-type ...

Secondary analysis of two randomized clinical trials probed atherosclerotic cardiovascular disease (ASCVD) risk in postmenopausal women with vasomotor symptoms initiating hormone therapy. Oral hormone ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that new clinical trial and outcomes research data will be presented at the European ...